Alliancebernstein L.P. Chinook Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$18.66 - $38.58 $14.1 Million - $29.1 Million	755,526 Added 1438.55%	808,046 $31 Million
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $324,162 - $475,890	17,400 Added 49.54%	52,520 $1.38 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $16,367 - $24,440	1,300 Added 3.84%	35,120 $614,000
Q1 2022 May 13, 2022	BUY	$12.02 - $16.69 $1,202 - $1,669	100 Added 0.3%	33,820 $553,000
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $22,449 - $35,343	2,100 Added 6.64%	33,720 $550,000
Q2 2021 Jul 30, 2021	BUY	$13.6 - $18.98 $100,640 - $140,452	7,400 Added 30.55%	31,620 $446,000
Q4 2020 Feb 08, 2021	BUY	$11.9 - $20.91 $288,218 - $506,440	24,220 New	24,220 $384,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.